Difference between revisions of "Olanzapine (Zyprexa)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties. Category:Drug...") |
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties. | Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties. | ||
| − | [[Category: | + | ==History of changes in PMDA indication== |
| + | *2017-12-25: New additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). | ||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Zyprexa | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intramuscular medications]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
[[Category:Dopamine receptor antagonist]] | [[Category:Dopamine receptor antagonist]] | ||
[[Category:Antipsychotic]] | [[Category:Antipsychotic]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1996]] |
Latest revision as of 01:54, 11 June 2023
Mechanism of action
Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties.
History of changes in PMDA indication
- 2017-12-25: New additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.).
Also known as
- Brand name: Zyprexa